Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin vs Ketamine in Treatment-resistant Depression
NCT05383313Phase 2Unknown
- Sponsor
- National Institute of Mental Health
- Start
- May 2021
- Primary completion
- Apr 2025
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of psilocybin in treatment-resistant depression (TRD), sponsored by National Institute of Mental Health. Status: unknown.
02
Drugs
psilocybin
03
Conditions
treatment-resistant depression (TRD)
Beyond the preview
Go deeper on NCT05383313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05383313.